company background image

Active Fine Chemicals DSE:ACTIVEFINE Stock Report

Last Price


Market Cap







07 Aug, 2022


Company Financials
ACTIVEFINE fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health2/6

ACTIVEFINE Stock Overview

Active Fine Chemicals Limited produces and sells bulk drugs/active pharmaceutical ingredients (APIs) and various laboratory reagents in Bangladesh.

Active Fine Chemicals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Active Fine Chemicals
Historical stock prices
Current Share Price৳19.60
52 Week High৳34.10
52 Week Low৳18.90
1 Month Change-10.09%
3 Month Change-13.27%
1 Year Change-18.67%
3 Year Change-19.34%
5 Year Change-39.00%
Change since IPO-30.30%

Recent News & Updates

Shareholder Returns

ACTIVEFINEBD PharmaceuticalsBD Market

Return vs Industry: ACTIVEFINE underperformed the BD Pharmaceuticals industry which returned -0.5% over the past year.

Return vs Market: ACTIVEFINE underperformed the BD Market which returned -8.9% over the past year.

Price Volatility

Is ACTIVEFINE's price volatile compared to industry and market?
ACTIVEFINE volatility
ACTIVEFINE Average Weekly Movement3.9%
Pharmaceuticals Industry Average Movement4.0%
Market Average Movement4.8%
10% most volatile stocks in BD Market6.7%
10% least volatile stocks in BD Market2.6%

Stable Share Price: ACTIVEFINE is not significantly more volatile than the rest of BD stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ACTIVEFINE's weekly volatility (4%) has been stable over the past year.

About the Company

2004n/aS. M. Rahman

Active Fine Chemicals Limited produces and sells bulk drugs/active pharmaceutical ingredients (APIs) and various laboratory reagents in Bangladesh. The company’s APIs include azithromycin dihydrate, erythromycin ethyl succinate, and erythromycin stearate for macrolide-antibiotics; esomeprazole magnesium trihydrates and pellets for anti-ulcerant; fluconazoles for anti-fungal; atorvastatin and rosuvastatin calcium for lipid-lowering; cetirizine and fexofenadine hydrochlorides, desloratadines, and ebastine for anti-histamine; and ciprofloxacin hydrochloride for anti-bacterial therapeutics. It also offers cefixime trihydrates and cefuroxime axetil for cephalosporin-antibiotics; metformin hydrochloride, sitagliptin phosphate monohydrate, vildagliptin, linagliptin, gliclizide, and glimepiride for anti-diabetic; pregabalin for anti-epileptic; paracetamol for analgesic and antipyrotic; losartan potassium and amlodipine besylate for anti-hypertensive; calcium orotate for use in calcium-supplement; sofosbuvir for anti-hepatitis-C; etoricoxib and ketorolac tromethamine for NSAID; and ticagrelor and amlodipine besylate for anti-platelet therapeutic areas, as well as solvents and solid reagents.

Active Fine Chemicals Fundamentals Summary

How do Active Fine Chemicals's earnings and revenue compare to its market cap?
ACTIVEFINE fundamental statistics
Market Cap৳4.70b
Earnings (TTM)৳54.82m
Revenue (TTM)৳1.70b


P/E Ratio


P/S Ratio

Is ACTIVEFINE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACTIVEFINE income statement (TTM)
Cost of Revenue৳1.32b
Gross Profit৳379.94m
Other Expenses৳325.11m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)0.23
Gross Margin22.36%
Net Profit Margin3.23%
Debt/Equity Ratio57.8%

How did ACTIVEFINE perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is ACTIVEFINE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACTIVEFINE?

Other financial metrics that can be useful for relative valuation.

ACTIVEFINE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.2x
Enterprise Value/EBITDA6.5x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does ACTIVEFINE's PE Ratio compare to its peers?

ACTIVEFINE PE Ratio vs Peers
The above table shows the PE ratio for ACTIVEFINE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average38.5x
ORIONINFU Orion Infusion
SILVAPHL Silva Pharmaceuticals
ADVENT Advent Pharma
SILCOPHL Silco Pharmaceuticals
ACTIVEFINE Active Fine Chemicals

Price-To-Earnings vs Peers: ACTIVEFINE is expensive based on its Price-To-Earnings Ratio (85.8x) compared to the peer average (38.5x).

Price to Earnings Ratio vs Industry

How does ACTIVEFINE's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

Price-To-Earnings vs Industry: ACTIVEFINE is expensive based on its Price-To-Earnings Ratio (85.8x) compared to the BD Pharmaceuticals industry average (22.4x)

Price to Earnings Ratio vs Fair Ratio

What is ACTIVEFINE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACTIVEFINE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio85.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ACTIVEFINE's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ACTIVEFINE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACTIVEFINE (BDT19.6) is trading above our estimate of fair value (BDT0.57)

Significantly Below Fair Value: ACTIVEFINE is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Active Fine Chemicals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Active Fine Chemicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Take a look at our analysis of ACTIVEFINE’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Active Fine Chemicals performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ACTIVEFINE has high quality earnings.

Growing Profit Margin: ACTIVEFINE became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: ACTIVEFINE's earnings have declined by 39.6% per year over the past 5 years.

Accelerating Growth: ACTIVEFINE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ACTIVEFINE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.9%).

Return on Equity

High ROE: ACTIVEFINE's Return on Equity (1%) is considered low.

Discover strong past performing companies

Financial Health

How is Active Fine Chemicals's financial position?

Financial Health Score


Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ACTIVEFINE's short term assets (BDT4.6B) exceed its short term liabilities (BDT3.4B).

Long Term Liabilities: ACTIVEFINE's short term assets (BDT4.6B) exceed its long term liabilities (BDT260.7M).

Debt to Equity History and Analysis

Debt Level: ACTIVEFINE's net debt to equity ratio (46.6%) is considered high.

Reducing Debt: ACTIVEFINE's debt to equity ratio has increased from 21.5% to 57.8% over the past 5 years.

Debt Coverage: ACTIVEFINE's debt is not well covered by operating cash flow (3.6%).

Interest Coverage: ACTIVEFINE's interest payments on its debt are not well covered by EBIT (0.3x coverage).

Balance Sheet

Discover healthy companies


What is Active Fine Chemicals's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: ACTIVEFINE's dividend (0.26%) isn’t notable compared to the bottom 25% of dividend payers in the BD market (1.2%).

High Dividend: ACTIVEFINE's dividend (0.26%) is low compared to the top 25% of dividend payers in the BD market (3.75%).

Stability and Growth of Payments

Stable Dividend: ACTIVEFINE is not paying a notable dividend for the BD market, therefore no need to check if payments are stable.

Growing Dividend: ACTIVEFINE is not paying a notable dividend for the BD market, therefore no need to check if payments are increasing.

Earnings Payout to Shareholders

Earnings Coverage: ACTIVEFINE is not paying a notable dividend for the BD market.

Cash Payout to Shareholders

Cash Flow Coverage: ACTIVEFINE is paying a dividend but the company has no free cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


S. M. Rahman (43 yo)

no data




Mr. S. M. Saifur Rahman serves as Managing Director and Chief Scientist of Active Fine Chemicals Ltd. Mr. Rahman has been a Director of Active Fine Chemicals Ltd. since December 1, 2004.He serves as a Dir...

Board Members

Experienced Board: ACTIVEFINE's board of directors are seasoned and experienced ( 10.9 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Active Fine Chemicals Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Active Fine Chemicals Limited
  • Ticker: ACTIVEFINE
  • Exchange: DSE
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ৳4.703b
  • Shares outstanding: 239.94m
  • Website:


  • Active Fine Chemicals Limited
  • Navana Osman @ Link
  • 214/D, Gulshan-Tejgaon Link Road
  • Dhaka
  • 1208
  • Bangladesh


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/07 00:00
Annual Earnings2021/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.